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ABSTRACT
Objectives: To respond to the primary safety objective of the Perinatal HIV Prevention Trial 1
(PHPT-1) by studying the evolution of haematological parameters according to zidovudine
exposure duration in HIV-1 infected pregnant women.
Design: Multicenter, randomized, double-blind, controlled trial of different durations of
zidovudine prophylaxis.
Setting: 27 hospitals in Thailand.
Participants: 1,436 HIV-infected pregnant women in PHPT-1.
Intervention: Zidovudine prophylaxis initiation at 28 or 35 wk gestation.
Outcome measures: Haemoglobin level, leucocytes, total lymphocyte counts, and absolute
neutrophil counts were measured at 26, 32, and 35 wk and at delivery. The evolution of
haematological parameters was estimated between 26 and 35 wk (zidovudine/placebo) and
between 35 wk and delivery to compare a long versus short zidovudine exposure. For each
parameter, linear mixed models were adjusted on baseline sociodemographic variables, HIV
clinical stage, CD4 count, and viral load.
Results: Between 26 and 35 wk, haemoglobin, leucocytes, and absolute neutrophil counts
decreased in zidovudine-exposed compared to unexposed women (mean difference [95% CI]
 0.4 [ 0.5 to 0.3], 423 [ 703 to 142], 485 [ 757 to 213], respectively). However, between
35 wk and delivery, the haematological parameters increased faster in women exposed to long
rather than short durations of zidovudine (0.1 [0.0 to 0.1]; 105 [18 to 191]; 147 [59 to 234],
respectively). At delivery, the differences were not statistically significant, except for mean
haemoglobin level, which remained slightly lower in the long zidovudine treatment group
(difference: 0.2 g/dl). Zidovudine had no negative impact on the absolute lymphocyte counts.
Conclusion: Zidovudine initiated at 28 wk gestation rather than 35 wk had a transient
negative impact on the evolution of haematological parameters, which was largely reversed by
delivery despite continuation of zidovudine. This result provides reassurance about the safety
of early initiation of zidovudine prophylaxis during pregnancy to maximize prevention of
perinatal HIV.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
www.plosclinicaltrials.org April | 2007 | e11 0001
PLoS CLINICAL TRIALSINTRODUCTION
In 1994, the PACTG 076-ANRS 024 trial showed the dramatic
efﬁcacy of zidovudine for the prevention of mother-to-child
transmissionof HIV:therate ofHIVtransmission was reduced
from 22.6% to 7.6% [1]. Since the release of this result,
prophylactic use of zidovudine has been recommended in all
industrialized countries [2]. To reduce the costs and increase
the feasibility of this intervention in developing countries,
short-course zidovudine, starting at 36 wk of pregnancy, was
evaluated [3–7]. However, longer treatment durations proved
more efﬁcacious [8] and since 2004, the World Health
Organization has recommended zidovudine initiation at 28
wk of gestation or as soon as possible thereafter, in women
who do not need treatment for their own health or when
antiretroviral combinations are not available [9].
Perinatal zidovudine exposure is associated with transient
anaemia and neutropenia [10–13], and bone marrow toxicity
of zidovudine, probably related to mitochondrial defects,
remains a concern [14–16]. The impact of zidovudine
exposure during pregnancy on haematological parameters
of HIV-infected women has been assessed in several placebo-
controlled studies. While one study showed a lower mean
haematocrit at delivery in women exposed to zidovudine [4],
other studies failed to demonstrate any effect of zidovudine
exposure on haematological parameters [1,5]. However, these
studies involved modest sample sizes (n ¼ 477 and n ¼ 280,
respectively), and haematological parameters were compared
only at delivery.
METHODS
Objective
The objective of the present study was to address the primary
safety objective of the Perinatal HIV Prevention Trial 1
(PHPT-1) [8]. The PHPT-1 objective was to compare in HIV-
infected women the safety and tolerance of long versus
shortened zidovudine regimens for the prevention of mother-
to-child transmission. In the present study, we assessed the
evolution of haematological parameters, including haemo-
globin level, leucocytes, absolute neutrophil counts, and total
lymphocyte counts, from 26 wk of gestation to delivery.
Design
PHPT-1 was a randomized, controlled, double-blind clinical
trial comparing the efﬁcacy of various durations of prophy-
lactic zidovudine for the reduction of mother-to-child HIV
transmission. Details of this trial (ClinicalTrials.gov [http://
clinicaltrials.gov/] identiﬁer: NCT00386230), trial design and
results have already been published [8]. The protocol received
ethical clearance from the Ethics Committees of the Thai
Ministry of Public Health, Chiang Mai University and the
Harvard School of Public Health.
Setting
Thestudywascarriedoutin27hospitalsthroughoutThailand.
Participants
The study population was composed of 1,436 HIV-infected
pregnant women enrolled in the PHPT-1. To be eligible for
PHPT-1, women had to have a haemoglobin level higher than
8 g/dl and an absolute neutrophil count higher than 750/mm
3.
Intervention
Pregnant women were randomly assigned to long or short
duration of zidovudine. Women assigned to the long group
receivedzidovudinefrom28wkofgestationtodelivery.Women
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Editorial Commentary
Background: Pregnant women who are infected with HIV are at high
risk of passing on the virus to their unborn baby during pregnancy,
labour, and breastfeeding. Around 15%–30% of babies born to HIV-
positive women will themselves become infected, if the woman avoids
breast-feeding but does not use any other means of preventing the virus
from being passed on. However, if a drug, zidovudine (AZT), is given
during pregnancy the chance of HIV being passed on to a baby drops
from around 23% to around 8%. In some settings it may not be realistic
to give the standard course of zidovudine, from 28 weeks of pregnancy,
because of its cost and complexity. A number of trials have therefore
looked at whether standard-course and short-course zidovudine are
equivalent at reducing the risk of passing on HIV from mother to baby.
One trial, the Perinatal HIV Prevention Trial-1 (PHPT-1) found that the
short treatment course was substantially less effective at preventing HIV
from being passed on from mother to baby. Current international
guidance therefore recommends starting zidovudine at 28 weeks of
pregnancy. However, zidovudine does have several side effects,
including anemia; it can also cause a drop in the levels of certain types of
white blood cell, and is thought to be toxic to bone marrow. The
researchers who had carried out the PHPT-1 trial therefore wanted to do
a subsequent analysis of data from that trial to find out whether there
were any differences in these safety outcomes between standard and
short course zidovudine.
What the trial shows: In total 1,436 women were recruited into the trial
and assigned to receive either zidovudine from 28 weeks of pregnancy
until delivery (standard course; 769 women), or from 35 weeks to
delivery (short course; 667). Blood tests were performed at 26, 32, and 35
weeks of pregnancy and then at delivery, and the main outcomes
assessed in this secondary analysis were the hemoglobin levels (to check
for anemia), and levels of white blood cells, including the levels of two
particular types (neutrophils and lymphocytes). The researchers found
that standard-course zidovudine resulted in a drop at 35 weeks in the
levels of hemoglobin and white blood cells, relative to short-course
zidovudine. However, by the time of delivery these levels had recovered
and no significant differences could be observed between the two arms
of the trial. Women receiving standard-course zidovudine were more
likely to experience severe anemia, which although a rare event in both
arms of the trial, could have serious outcomes.
Strengths and limitations: The original trial from which these data were
collected was a relatively large, randomized study and in which there
was a low rate of loss to follow up. Although no formal sample size
calculation was performed for the analyses presented here, the study
probably had sufficient power to detect small differences in the
outcomes assessed. A key limitation of this study is that the analyses
presented here are a secondary exploration of data from the PHPT-1 trial
and should therefore be seen as hypotheses to test in further studies,
rather than as definitive conclusions.
Contribution to the evidence: The analyses presented here add to the
findings of the parent trial, PHPT-1, by providing additional data about
the toxicity of zidovudine. Other trials have not clearly established
whether there are differences between short- and standard-course
zidovudine in terms of their toxicity. The findings support current
guidelines recommending standard-course zidovudine therapy for HIV-
positive pregnant women. It is also crucial that efforts are made to
ensure women worldwide can get access to facilities for monitoring the
status of their HIV infection, and then receive highly active antiretroviral
therapy when it is needed.
The Editorial Commentary is written by PLoS staff, based on the reports of the
academic editors and peer reviewers.assigned to the short group received placebo from 28 wk of
gestation and then received zidovudine from 35 wk to delivery.
Outcome Measures
Haematological measurements were ﬁrst performed at the
pre-entryvisit,plannedat26wkgestation,thenat32and35wk
gestationandatdeliveryuponadmissiontothematernityunit.
We deﬁned anaemia as haemoglobin level lower than 11 g/dl
following the conventional threshold proposed by the WHO
guidelines for pregnant women in the third trimester [17]. We
also used tables from the National Institutes of Health (NIH),
National Institute of Allergy and Infectious Diseases (NIAID),
Division of AIDS for grading the severity of anaemia [18]. Mild
anaemia (grade 1) was deﬁned as haemoglobin levels between
8.5 and 10.0 g/dl; moderate anaemia (grade 2) between 7.5 and
8.4 g/dl, severe anaemia (grade 3) between 6.5 and 7.4 g/dl and
potentially life-threatening anaemia (grade 4) as lower than
6.5 g/dl. We deﬁned leucopenia as leucocyte counts below
4,000/mm
3; neutropenia as absolute neutrophil count below
1,500/mm
3; and lymphopenia as absolute lymphocyte count
below 1,000/mm
3.
To identify possible inconsistencies, the haematological
values of each woman were plotted in a chart and any value
above or below 3 standard deviations of the mean were
checked against the original laboratory result slip. Only 5 out
of 19,000 measurements were found to be inconsistent and
were recorded as missing.
For women who experienced haemorrhage-related trans-
fusion, the haematological parameters immediately before
and after transfusion were not taken into account. For
women who experienced transfusion unrelated to a haemor-
rhage, the haematological parameters before transfusion
were carried forward until delivery.
Statistical Methods
The evolution of haematological parameters was examined
between26wkofgestationanddelivery,andtheobservedmeans
at 26, 32, and 35 wk of gestation and at delivery were compared
according to the treatment arms using Student’s t-test.
To analyse the evolution of haematological parameters,
mixed effects models were used to take into account
correlations between measurements within the same woman
and variability between women [19]. Because of possible
treatment period interaction, instead of considering the
treatment period as a whole, haematological evolutions were
estimated during two periods: ﬁrst, between the pre-entry
visit (26 wk) and the 35-wk visit; and second, between the 35-
wk visit and delivery, while all women were exposed to
zidovudine. The regression coefﬁcients were compared using
the Wald’s test.
The evolution of haematological parameters during the
ﬁrst period were compared between women randomly
exposed to zidovudine versus placebo, after adjustment on
variables at baseline, including maternal age, body mass
index, HIV clinical stage, CD4 count, viral load, parity,
education level, type of employment, and region of residence.
As the ﬁrst blood test was scheduled two weeks prior to
zidovudine initiation, the zidovudine exposure was used as a
time-varying variable.
The evolution of haematological parameters during the
second period were compared between the two groups of
women according to their previous exposure to zidovudine
between 28 to 35 wk of gestation, after adjustment on the
variables mentioned above and the value of the considered
haematological parameter at 35 wk of gestation.
The predicted values of each haematological parameter
were estimated at 35 wk and at delivery. The goodness of ﬁt of
the models was checked by plotting the residuals. The p-
values reported are two-tailed, and an alpha level of 0.05 was
used to assess statistical signiﬁcance.
All analyses were performed using SAS statistical software
(version 8.2, SAS Institute, http://www.sas.com).
RESULTS
Participants and Baseline Data
The baseline characteristics of 1,436 pregnant HIV-infected
women included in the PHPT-1 trial between June 1997 and
December 1999 have already been described [8]. The main
characteristics are described in Table 1, and participant ﬂow
is described in Figure 1. In total, 667 HIV-1 women were
randomized to the short zidovudine regimen and 769 women
to the long regimen.
In the entire study population, at pre-entry visit planned at
26 wk of gestation, the median (interquartile range [IQR])
haemoglobin level was 10.7 (10.0 to 11.4) g/dl, the leucocyte
count was 8,670 (7,200 to 10,300) cells/mm
3, the absolute
.......................................................................................................................................................................................
Table 1. Maternal Characteristics at 26 Wk Gestation According to Randomization Arm
Characteristics Short Regimen Long Regimen Total
Total, n 667 769 1,436
Median age, y (IQR) 25.0 (21.9 to 28.5) 24.7 (22.1 to 28.4) 24.9 (21.9 to 28.5)
Primiparity, n (%) 297 (44.5) 309 (40.2) 606 (42.2)
No education or primary school, n (%) 433 (64.9) 504 (65.5) 937 (65.3)
Manual employment
a, n (%) 458 (68.7) 531 (69.1) 989 (68.9)
Median body mass index, kg/m
2 (IQR) 23.2 (21.3 to 25.1) 23.1 (21.5 to 25.3) 23.1 (21.5 to 25.1)
WHO clinical stage I, n (%) 587 (88.0) 683 (88.8) 1,270 (88.4)
Median CD4 count, cells/mm3 (IQR) 360 (230 to 500) 360 (240 to 519) 360 (240 to 510)
Median viral load, log10 copies HIV RNA/ml (IQR) 3.98 (3.40 to 4.50) 3.88 (3.32 to 4.47) 3.93 (3.34 to 4.48)
Region of residence: North, n (%) 258 (38.7) 295 (38.4) 553 (38.5)
Centre, n (%) 114 (17.1) 137 (17.8) 251 (17.5)
South, East, and West, n (%) 295 (44.2) 337 (43.8) 632 (44.0)
aAgriculture, fishery, or daily worker.
doi:10.1371/journal.pctr.0020011.t001 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
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Haematological Safety and Perinatal ZDVneutrophil count was 6,002 (4,896 to 7,300) cells/mm
3, and the
absolutelymphocytecountwas1,919(1,476to2,425)cells/mm
3.
Median (IQR) length of gestation was 39.0 (38.0 to 40.0) wk.
Median gestational ages at pre-entry and at randomization
visit were 25.7 (24.6 to 26.4) wk and 27.9 (27.3 to 28.1) wk,
respectively. The median duration of the ﬁrst period (pre-
entry to 35-wk visit) and the second period (35-wk visit to
delivery) considered for analysis were 9.0 (8.0 to 9.9) wk and
4.3 (3.9 to 4.8) wk, respectively. The durations of the periods
did not differ signiﬁcantly according to randomization arms.
Outcomes
The observed evolutions of the mean haemoglobin, leucocyte,
absolute neutrophil count, and absolute lymphocyte count,
between 26 wk of gestation and delivery, are presented in
Figure 2 by randomization arms. The mean haemoglobin level
increased steadily between 26 wk and delivery in women
randomized to the short regimen (Figure 2A). In women
randomized to the long regimen, haemoglobin decreased
slightly from 26 to 32 wk, and then increased until delivery.
The mean haemoglobin levels, similar at pre-entry in both
groups, were signiﬁcantly lower in women randomized to the
long regimen at 32 and 35 wk gestation and, to a lesser extent,
at delivery. The mean leucocyte (Figure 2B) and neutrophil
(Figure 2C) counts decreased slightly until 35 wk and then
increased sharply until delivery, with a more rapid decrease
and subsequent increase in women randomized to the long
regimen. The mean counts were signiﬁcantly lower at 32 and
35 wk gestation in women randomized to the long regimen,
but did not differ between the two groups at delivery. The
lymphocyte counts (Figure 2D) remained stable until 35 wk of
gestation and then increased until delivery, with no differ-
ence between the two groups.
We have also presented the evolution of the haematological
parameters from a safety perspective. Table 2 presents the
percentages of women with anaemia at different severity
grades (following the WHO guidelines [17] as well as those of
the table of the National Institutes of Health, National
Institute of Allergy and Infectious Diseases, Division of AIDS
[18]) and the percentages of leucopenia, neutropenia, and
lymphopenia at pre-entry, at 32 and 35 wk of gestation, and at
delivery, according to the randomization arms.
Between the pre-entry and 35-wk visits, we found that, after
adjustment on variables at baseline, zidovudine intake still
had a negative impact on the evolution of haemoglobin level,
leucocyte counts, and absolute neutrophil counts, as shown
by the mean (95% conﬁdence interval [CI]) decrease
associated with exposure to zidovudine,  0.4 ( 0.5 to  0.3)
g/dl/wk, p , 0.001; 423 ( 703 to 142) cells/mm
3/wk, p¼0.003;
 485 ( 757 to  213) cells/mm
3/wk, p , 0.001, respectively
(Table 3). Zidovudine exposure, however, had no negative
impact on the evolution of absolute lymphocyte counts (166
[0 to 332] cells/mm
3/wk, p ¼ 0.05).
During the second period, between the 35-wk visit and
delivery, after adjustment, the haemoglobin level, leucocyte
count, and absolute neutrophil count increased signiﬁcantly
faster in women randomized to the long regimen than women
in the short regimen, as shown by the mean (95% CI) increase
associated with exposure to zidovudine of 0.1 (0.0 to 0.1) g/dl/
wk, p , 0.001, 105 (18 to 191) cells/mm
3/wk, p¼0.02, 147 (59 to
234) cells/mm
3/wk, p ¼ 0.001, respectively. There were no
differences in the absolute lymphocyte counts (Table 3).
The predicted means are described in Table 3.
Other than zidovudine exposure, the factors independently
associated with a negative evolution of haematological
parameters were low body mass index, multiparity, low CD4
Figure 1. Flow of Participants
doi:10.1371/journal.pctr.0020011.g001
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Haematological Safety and Perinatal ZDVcount, an advanced HIV clinical stage, and high baseline viral
load (unpublished data).
Blood Transfusions
Overall, eight (0.6%) pregnant women received blood trans-
fusions. All were exposed to zidovudine from 28 wk gestation
(8/754 versus 0/656, p ¼ 0.01). Among these women, two were
transfused because of a haemorrhage (at delivery and at 7 d
before delivery). One woman with a thalassemia trait received
packed red cell transfusions at 45 and 37 d before delivery.
The remaining ﬁve women were transfused at 0, 2, 4, 25 and 64
d before delivery because of anaemia, including one woman
with a haemoglobin level of 4.6 g/dl who delivered a stillborn.
DISCUSSION
Interpretation
This study showed that women initiating zidovudine at 28 wk
gestation had a transient decrease of haemoglobin level,
leucocytes count, and absolute neutrophil count compared to
women initiating zidovudine at 35 wk. However, by the time
of delivery this initial decrease reversed in women random-
ized to the long regimen as compared to women randomized
in the short regimen, except for haemoglobin levels, which
remained lower by 0.2 (0.1 to 0.3) g/dl in women with longer
exposure to zidovudine. No negative effect of zidovudine
exposure could be detected on the lymphocyte count
evolution from 26 wk of gestation to delivery.
This analysis conﬁrms that the severity of haematological
toxicity of zidovudine is associated with the duration of
exposure. Indeed, at delivery, the percentages of grade 4
anaemia were higher in women randomized to the long
regimen as compared with those randomized to the short
regimen (0.9% versus 0.0%, respectively). Although adverse
events such as severe anaemia, leucopenia, neutropenia, and
lymphopenia were uncommon, they should not be taken
lightly because of their life-threatening potential. Yet the rate
of women who were transfused was of the same magnitude as
has been seen in other studies of HIV-uninfected women not
receiving zidovudine [20,21]. No woman stopped the study
treatment because of haematological toxicity, although one
woman exposed to zidovudine from 28 wk of gestation
developed severe anaemia and delivered a stillborn. This
womanpresentedatpre-entrybiologicalparametersknownto
be associated with anaemia, such as low CD4 count (80 cells/
mm
3)andhighHIVRNAviralload(5.33logcopies/ml)[22–24].
Women in the study were provided with iron supplemen-
tation, according to the national recommendation [25].
However, we had no information about adherence to this
recommendation. As the duration of zidovudine exposure
was assigned randomly, supplementation is likely to be
balanced among the randomized groups in each site and
should not have been a source of bias.
More than 90% of the laboratory results for haemoglobin
level, leucocyte count, and neutrophil count were available at
each visit, with no difference between the randomization
Figure 2. Haematological Parameters between 26 Weeks’ Gestation and Delivery in HIV-Infected Women According to Zidovudine Exposure
Measurements occurred at the same visit in the two groups. All values are expressed as means and 95% CIs. Comparison of long (zidovudine exposure from 28
wk of gestation) versus short (zidovudine exposure from 35 wk of gestation) regimens was done by Student’s t-test. Broken line, short arm; solid line, long arm.
*p , 0.05, **p , 0.01, ***p , 0.001.
(A) Haemoglobin level.
(B) Leucocyte counts.
(C) Absolute neutrophil counts.
(D) Absolute lymphocyte counts.
doi:10.1371/journal.pctr.0020011.g002
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remained large enough to demonstrate small statistical
differences, even if the clinical signiﬁcance appears small.
For the lymphocyte counts, however, only 33% of the
laboratory results were available at 32 and 35 wk of gestation
and at delivery. It is possible that the absence of signiﬁcant
difference in lymphocyte evolution between the two groups
could be explained by a lack of power.
Generalizability
The observed evolution pattern of haematological parameters
in women randomized to the short regimen was similar to the
physiologic evolution generally described in pregnant women
during the third trimester of pregnancy [26]. In contrast, in
women randomized to the long regimen, the evolution of the
haemoglobin, leucocytes, and neutrophils was signiﬁcantly
slowed down until 35 wk, followed by a clear catch-up
phenomenon during the last weeks of pregnancy. It should
be noted that, in the absence of a control group of women
receiving no zidovudine during pregnancy, it is impossible to
evaluate the actual impact of zidovudine from 35 wk of
gestation until delivery. It is likely that, in the absence of
zidovudine exposure, the values of haematological parameters
at delivery would have been higher, and this may explain, in
part, the apparent convergence of the two groups at delivery.
Interestingly, the 37.4% prevalence of anaemia (haemoglo-
bin ,11 g/dl) at delivery, observed in our study was similar to
recent national estimates of 38.6% in Thailand [27]. Our
results on the potential toxicity of zidovudine during
pregnancy cannot be directly compared with other studies
because of the different durations of zidovudine exposure,
haematological parameters considered, and overall study
designs. In a placebo-controlled trial of the efﬁcacy of a
short course zidovudine regimen from 36 wk gestation in
Thailand, pregnant women exposed to zidovudine had a
signiﬁcantly lower mean haematocrit than unexposed wom-
en, 31.9% versus 33.0%, p ¼ 0.03 [4]. In our study, the mean
haematocrit level at delivery was higher—34.8% in women
exposed to zidovudine from 35 wk (unpublished data). The
absence of difference in the mean haemoglobin level at
delivery in two other placebo-controlled trials may be
explained by their relatively limited sample size [1,5].
From 26 wk of gestation to delivery, CD4 counts less than
200 cells/mm
3, HIV RNA viral load higher than 50,000 copies/
ml, and an advanced HIV clinical stage were independently
associated with a negative evolution of the haematological
parameters. Similar ﬁndings have already been reported
[22,23], emphasising the need for systematic CD4 testing
during pregnancy and access to highly active antiretroviral
therapy for immunocompromised women [24]. This result is
consistent with the hypothesis that HIV, per se, may be
associated with the development of anaemia, presumably
because of direct effects of the virus on bone marrow
suppression and reduction of erythropoietin production and
response [28–32].
Overall Evidence
The beneﬁt of early zidovudine initiation, namely, its greater
efﬁcacyinreducingperinataltransmission[8],isnotoutweighed
by signiﬁcant disadvantages for the mother in terms of toxicity.
As more and more women receive antiretroviral therapies
during pregnancy, monitoring of the haematological effects of
these therapies remains paramount to ensure their safety.
SUPPORTING INFORMATION
CONSORT Checklist
Found at doi:10.1371/journal.pctr.0020011.sd001 (27 KB PDF).
Trial Protocol
Found at doi:10.1371/journal.pctr.0020011.sd002 (336 KB PDF).
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